745, p < 001), and the eradication of H pylori revealed a stati

745, p < .001), and the eradication of H. pylori revealed a statistical significant difference in different subgroups (χ2 = 11.300, p = .001). Our findings showed that many H. pylori-positive subjects diagnosed as “functional dyspepsia”

were actually chronic gastritis patients, especially the EPS cases who are more likely to be patients with “active gastritis under microscope,” and also benefit most from the treatment of proton-pump BMS-907351 in vitro inhibitors or eradication of H. pylori. “
“The eradication rate with PPI-based standard triple therapy for Helicobacter pylori infection has fallen considerably. One recent innovation is sequential therapy with PPI and three antibiotics, but the complexity of this regimen may reduce its usability. Concomitant administration of nonbismuth quadruple drugs (concomitant

therapy) is also an effective treatment strategy. To investigate which regimen is a reasonable choice for Korean population, we performed two pilot studies with sequential Navitoclax and concomitant therapies. A total of 164 patients with proven H. pylori infection randomly received 14 days of sequential (n = 86) or concomitant (n = 78) therapies. The sequential group received 20 mg rabeprazole and 1 g amoxicillin (first week), followed by 20 mg rabeprazole, 500 mg clarithromycin, and 500 mg metronidazole (second week). The concomitant group received 20 mg rabeprazole, 1 g amoxicillin, 500 mg clarithromycin, and 500 mg metronidazole for 2 weeks. All drugs Sclareol were administered BID. Helicobacter pylori status was confirmed 4 weeks later, after completion of treatment by 13C-urea breath test. The intention-to-treat and per-protocol eradication rates were 75.6% (95% CI, 66.3–84.9) and 76.8% (95% CI, 67.1–85.5) in the sequential group, and 80.8% (95% CI, 71.8–88.5) and 81.3% (95% CI, 71.6–90.7)

in the concomitant group. There were no significant between-group differences, in regard to the eradication rates, compliance, or side effects. The most common side effects were bitter taste, epigastric soreness, and diarrhea. Two-week concomitant and sequential therapies showed suboptimal efficacies. However, considering high antibiotics resistance, either of these two regimens may be a reasonable choice for Korean population. “
“Helicobacter pylori represents the major etiologic agent of gastritis, gastric, and duodenal ulcer disease and can cause gastric cancer and mucosa-associated lymphoid tissue B-cell lymphoma. It is clear that the consequences of infection reflect diverse outcomes of the interaction of bacteria and host immune system. The hope is that by deciphering the deterministic rules – if any – of this interplay, we will eventually be able to predict, treat, and ultimately prevent disease. Over the past year, research on the immunology of this infection started to probe the role of small noncoding RNAs, a novel class of immune response regulators.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>